Literature DB >> 6580526

Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia.

G J Mufti, D G Oscier, T J Hamblin, A J Bell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6580526     DOI： 10.1056/NEJM198312293092618

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells.

Authors:  C S Chan; G P Schechter
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Refractory anaemias.

Authors:  A K Saraya; P S Dhot; R Saxena
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

Review 3.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

Review 4.  Hematopoietic growth and differentiation factors and the reversibility of malignancy: cell differentiation and by-passing of genetic defects in leukemia.

Authors:  L Sachs
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.

Authors:  Maël Heiblig; Mohamed Elhamri; Isabelle Tigaud; Adriana Plesa; Fiorenza Barraco; Hélène Labussière; Sophie Ducastelle; Mauricette Michallet; Franck Nicolini; Claudiu Plesa; Eric Wattel; Gilles Salles; Xavier Thomas
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-01-01       Impact factor: 2.576
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.